| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| ALPINE IMMUNE SCIENCES, INC. | 10%+ Owner | Common Stock | 6,582,380 | $83,859,521 | $12.74 | 18 Jan 2024 | Direct |
| BeyondSpring Inc. | 10%+ Owner | Ordinary Shares | 1,617,409 | $2,814,291 | $1.74 | 16 Oct 2025 | By Decheng Capital China Life Sciences USD Fund II, L.P. |
| BeyondSpring Inc. | 10%+ Owner | Ordinary Shares | 1,518,893 | $2,673,251 | $1.76 | 17 Oct 2025 | By Decheng Capital China Life Sciences USD Fund III, L.P. |
| Cue Health Inc. | 10%+ Owner | Common Stock | 8,192,468 | $2,457,740 | $0.3000 | 28 Sep 2021 | Direct |
| BeyondSpring Inc. | 10%+ Owner | Ordinary Shares | 891,734 | $1,551,617 | $1.74 | 16 Oct 2025 | By Decheng Capital Global Healthcare Fund (Master), LP |
| ALPINE IMMUNE SCIENCES, INC. | 10%+ Owner | Warrant (right to buy) | 0 | 18 Jan 2024 | Direct | ||
| Cue Health Inc. | 10%+ Owner | Series C-1 Preferred Stock | 0 | 28 Sep 2021 | Direct |